- Home
- PLX vs THRD Comparison
PLX vs THRD Comparison
Compare PLX & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- THRD
- Stock Information
- Founded
- PLX 1993
- THRD 2019
- Country
- PLX United States
- THRD United States
- Employees
- PLX N/A
- THRD N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- THRD Health Care
- Exchange
- PLX Nasdaq
- THRD Nasdaq
- Market Cap
- PLX 160.2M
- THRD 164.2M
- IPO Year
- PLX 1998
- THRD 2022
- Fundamental
- Price
- PLX $2.87
- THRD $5.15
- Analyst Decision
- PLX Strong Buy
- THRD Hold
- Analyst Count
- PLX 1
- THRD 3
- Target Price
- PLX $15.00
- THRD $5.00
- AVG Volume (30 Days)
- PLX 753.1K
- THRD 1.1M
- Earning Date
- PLX 05-09-2025
- THRD 05-19-2025
- Dividend Yield
- PLX N/A
- THRD N/A
- EPS Growth
- PLX N/A
- THRD N/A
- EPS
- PLX 0.04
- THRD N/A
- Revenue
- PLX $53,399,000.00
- THRD N/A
- Revenue This Year
- PLX $65.02
- THRD N/A
- Revenue Next Year
- PLX $57.34
- THRD N/A
- P/E Ratio
- PLX $79.67
- THRD N/A
- Revenue Growth
- PLX N/A
- THRD N/A
- 52 Week Low
- PLX $0.82
- THRD $3.18
- 52 Week High
- PLX $3.10
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- PLX 56.85
- THRD 76.77
- Support Level
- PLX $2.70
- THRD $5.13
- Resistance Level
- PLX $2.64
- THRD $5.25
- Average True Range (ATR)
- PLX 0.17
- THRD 0.05
- MACD
- PLX -0.01
- THRD -0.03
- Stochastic Oscillator
- PLX 61.67
- THRD 41.18
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.